8-K: Verrica Pharmaceuticals and Torii Pharmaceutical Amend Agreement to Fund Global Phase 3 Trial for Common Warts Treatment

Verrica Pharmaceuticals and Torii Pharmaceutical have amended their collaboration agreement to equally split the costs of a global Phase 3 clinical trial for YCANTH in the treatment of common warts.

Summary

• Verrica Pharmaceuticals and Torii Pharmaceutical have amended their existing collaboration agreement to jointly fund a global Phase 3 clinical trial for YCANTH (VP-102) for the treatment of common warts.
• The costs of the trial will be split equally between the two companies, with Torii initially funding all costs and Verrica repaying their portion with interest.
• Verrica's repayment will accrue interest at the greater of the one-month Secured Overnight Financing Rate plus 2% or 6%.
• Torii has the right to offset Verrica's portion of the costs against future milestone payments owed to Verrica.
• If Torii does not receive full repayment within 60 months, they can invoice Verrica for the remaining amount.
• Torii has the right to terminate the agreement under certain conditions, but not before the trial database lock or termination of the trial.
• Verrica issued Torii a warrant to purchase up to 500,000 shares of common stock at an exercise price of $9.56 per share.
• The warrant shares will vest upon the first patient being dosed, the database lock, and the submission of a New Drug Application (NDA) for common warts.
• The global Phase 3 trial is expected to begin in the first half of 2025.
• Verrica believes the common warts market represents a multibillion-dollar commercial opportunity, with approximately 22 million patients in the U.S. and a similar number in the EU.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a significant step forward in the development of YCANTH for common warts. The cost-sharing agreement and potential market opportunity are encouraging, but there are also risks associated with clinical trials and repayment obligations.

Positives

• The cost-sharing agreement with Torii reduces the financial burden on Verrica for the Phase 3 trial.
• The amendment allows Verrica to advance YCANTH for common warts into a global pivotal Phase 3 trial.
• The potential for a high degree of call point overlap and marketing synergies with its molluscum promotion of YCANTH.
• The common warts market is large and underserved, representing a significant commercial opportunity.
• The warrant issued to Torii provides an incentive for their continued collaboration.
• Positive Phase 2 data for YCANTH in common warts supports the potential for success in Phase 3.

Negatives

• Verrica will need to repay Torii for half of the trial costs, plus interest, which could impact their cash flow.
• Torii has the right to offset Verrica's repayment against future milestone payments, potentially reducing Verrica's revenue.
• Torii can invoice Verrica for the remaining amount if not repaid within 60 months.
• The agreement includes a termination clause that could impact Verrica if certain conditions are met.
• The warrant issued to Torii could dilute existing shareholders.

Risks

• The clinical trial may not be successful, and regulatory approval may not be granted.
• The trial is subject to feedback from the FDA and PMDA, which could delay the start of the trial.
• There is a risk that Torii may terminate the agreement under certain conditions.
• The repayment obligation to Torii could strain Verrica's finances.
• The market for common warts treatment may not be as large as anticipated.
• The company is reliant on third parties for the development and commercialization of its products.

Future Outlook

Verrica anticipates that positive data from the global Phase 3 clinical trial could lead to a sNDA submission in the U.S. and potential marketing authorizations in other territories, including the EU. The company expects the trial to begin in the first half of 2025.

Management Comments

• Ted White, President and CEO of Verrica Pharmaceuticals, stated that they are pleased to announce the amendment to their license agreement with Torii Pharmaceutical to advance YCANTH into a global pivotal Phase 3 clinical trial for the treatment of common warts.
• Ted White also noted that Torii has been an outstanding partner in the development of YCANTH for molluscum contagiosum and they look forward to their continued collaboration.

Industry Context

This announcement is significant as it addresses a large unmet need in dermatology, with common warts affecting millions of people and having no FDA-approved treatments. The collaboration between Verrica and Torii leverages their existing partnership and aims to bring a new treatment option to market.

Comparison to Industry Standards

• The agreement between Verrica and Torii is similar to other pharmaceutical collaborations where costs and risks are shared to develop new treatments.
• The 51% complete clearance rate in the Phase 2 trial is promising compared to other treatments for common warts, which often have lower efficacy rates.
• The estimated 22 million patients in the U.S. with common warts highlights the large market opportunity, comparable to other major dermatological conditions.
• The milestone payment of $8 million upon the first patient dosed in Japan is a common practice in pharmaceutical licensing agreements.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of YCANTH for common warts.
• Employees may benefit from the company's growth and development.
• Patients with common warts may benefit from a new treatment option.
• Torii Pharmaceutical will benefit from the potential commercialization of YCANTH in Japan.
• Creditors may be impacted by the repayment obligations to Torii.

Next Steps

• The companies will seek feedback from the FDA and PMDA on the proposed design of the Phase 3 clinical trial.
• The global Phase 3 clinical trial is expected to begin in the first half of 2025.
• Verrica will submit a sNDA in the U.S. seeking FDA approval for the use of YCANTH for the treatment of common warts if the Phase 3 trial is successful.
• Verrica may seek future marketing authorizations in territories outside the U.S. and Japan.

Key Dates

Keywords

YCANTH, VP-102, common warts, clinical trial, Phase 3, Torii Pharmaceutical, licensing agreement, dermatology, FDA, warrant